The potential effect of blocking the CCR5 receptor on HIV disease progression biomarkers is not well understood. We showed that an 8-day maraviroc (MVC) monotherapy clinical test (MCT) can be used in selecting patients to receive MVC-containing combined antiretroviral therapy (cART). Using this MCT model, we assessed the effect of MVC on several HIV disease progression biomarkers during the MCT (MVC-specific effect) and following short-term (12-week) cART. We compared 45 patients on MVC monotherapy with a control group of 25 patients on MVC-sparing cART. We found that MVC did not modify any biomarkers in patients that had no virological response after the MCT. MVC-specific effects in patients with virological responses included increased CD8 ؉ T-cell activation and senescence levels, preservation of an increase in soluble CD14 (sCD14), and a decrease in D dimer levels. After 12 weeks, MVC-containing cART increased CD8 ؉ T-cell counts and preserved CD4 ؉ T-cell senescence levels compared with MVC-sparing cART. Moreover, there was a decrease in sCD14 levels in patients that received MVCcontaining cART. In conclusion, effects compatible with CD8
T he introduction of highly active antiretroviral therapy has dramatically decreased AIDS-related mortality and morbidity (19) . However, non-AIDS-defining illnesses have increased despite the use of combined antiretroviral therapy (cART) (18) . Several biomarkers, such as T-cell activation (12, 15, 17) , T-cell senescence (6) , soluble CD14 (sCD14), D dimer, and highsensitivity C-reactive protein (hsCRP) (4, 16, 24) , have been associated with death and clinical progression in HIV infection. These biomarkers remain elevated in HIV patients despite suppressive cART. Thus, it is important to explore whether new drugs can have an impact on HIV progression-related biomarkers. Maraviroc (MVC) (7), the first CCR5 (R5) antagonist approved for the treatment of HIV-1 infection, has been proposed as a drug with an immunomodulatory effect independent of its antiviral activity (1, 23, 25) . Moreover, it has been recently suggested that MVC-containing cART can facilitate a greater reduction in immune activation and inflammation markers than conventional cART (10) . However, in these studies, other antiretroviral drugs combined with MVC may have masked the net MVC immunomodulatory effect.
Our group has developed the MVC clinical test (MCT) (11) , in which the virological response to monotherapy with MVC treatment for 8 days is used to select patients for R5 antagonist use in subsequent cART. Thus, the MCT constitutes a unique scenario for testing the short-term effect of the R5 blockade. In this sense, we found a higher CD8 ϩ T-cell gain in patients undergoing MCT treatment than with the 8-day effect of conventional cART (20) . However, the potential MVC-specific effects on HIV disease progression biomarkers were not evaluated.
Our aim was to assess the effect of MVC on several immunological and HIV disease progression-related biomarkers after MVC monotherapy (MVC-specific effect) and following shortterm (12-week) cART.
MATERIALS AND METHODS
Patients. Since July 2008, the MCT has been routinely used at the Infectious Diseases Service at Virgen del Rocío University Hospital for selecting candidate patients to receive MVC-containing cART (11) . Briefly, the MCT consists of 8 days of MVC monotherapy exposure. The subsequent virological response is analyzed to determine whether MVC should be included in the subsequent round of cART. The MCT is considered positive if a significant viral load reduction, defined as a reduction of Ն1 log 10 HIV RNA copy/ml, or an undetectable viral load (Ͻ40 HIV RNA copies/ ml) was achieved on day 8 after MVC monotherapy. All of the patients were asymptomatic when the study was performed, and the inclusion criteria for the MCT have been previously defined (11) . Inclusion criteria include (i) a persistently detectable viral load (Ͼ40 HIV RNA copies/ml) during the last 6 months, (ii) no highly active antiretroviral therapy (HAART) modification in the last 6 months, (iii) no HAART reintroduction in the last 6 months in patients undergoing previous supervised treatment interruption (STI), (iv) no previous treatment with coreceptor antagonists, and (v) available future therapeutic options apart from MVC. For the purpose of the present study, a subgroup of patients with available samples was included. Three groups were defined as follows. (i) The MCT-positive group (MCT ϩ ) contains patients with a positive response after the MCT (n ϭ 30). (ii) The MCT-negative group (MCT Ϫ ) includes patients without a virological response after the MCT (n ϭ 15). MVCcontaining and MVC-sparing cART, respectively, was started after the MCT in these patients. (iii) The control group contains 25 consecutive asymptomatic treatment-naive patients starting conventional MVC-sparing cART (n ϭ 25). The inclusion period for these patients was the same as those for the MCT groups.
All patients were evaluated at baseline and on day 8. Furthermore, in addition to the evaluation time points in our previous study design (20) , patients on follow-up were analyzed at baseline and after 12 weeks on cART. The study design is shown in Fig. 1 . Patients, or legal guardians of patients under 18 years of age, provided written informed consent, and the ethical committee of the hospital approved the study.
Laboratory tests. Plasma HIV-1 RNA was measured in fresh samples by quantitative PCR (Cobas AmpliPrep/Cobas TaqMan HIV-1 test; Roche Molecular Systems, Basel, Switzerland) according to the manufacturer's instructions. The lower detection limit was 40 HIV-1 RNA copies/ ml. A qualitative PCR amplification was performed for plasma hepatitis C virus (HCV) RNA amplification (Cobas Amplicor; Roche Diagnostics, Barcelona, Spain), and the lower detection limit was 15 IU/ml. CD4 ϩ T-cell counts were determined in fresh whole blood using the Epics XL-MCL flow cytometer (Beckman-Coulter Inc., California) according to the manufacturer's instructions.
HIV disease progression-associated biomarkers. Predictor biomarkers of all causes of mortality in HIV-infected patients (3, 4, 16, 24) were assayed on available frozen samples by following the manufacturer's instructions with minor modifications. sCD14 levels, a monocyte activation biomarker, were assayed with the commercially available enzyme-linked immunosorbent assay (ELISA) kit on sera diluted 0.01% in duplicate wells (R&D Systems). D dimer levels, a thrombotic activity biomarker, were measured in an automated latex-enhanced immunoassay for the quantitative determination of D dimer in plasma samples (HemosIL D-Dimer HS 500; Instrumentation Laboratory). Levels of hsCRP, an inflammation marker, were determined with an immunoturbidimetric assay on sera using Roche automated clinical chemistry analyzers by following the manufacturer's instructions. The sensitivity and linearity ranges were assayed in every biomarker, and they fit with the range indicated in the respective assay kit as described by the manufacturer's instructions. There was an interassay linearity of the samples of Ͼ90% in all the assays. All the sample measures were above the detection limit of every assay.
T-cell immunophenotyping. CD4 ϩ and CD8 ϩ peripheral T-cell subsets were positively selected from available frozen peripheral blood mononuclear cells (PBMCs) using magnetic microbeads from magnetically activated cell sorting (MACS) cell separation reagents (Miltenyi Biotec, Germany) according to the manufacturer's instructions. The purity obtained from the separation of both T-cell subsets was routinely Ͼ90%. CD4 ϩ and CD8 ϩ T cells were then stained with the conjugated monoclonal antibodies CD28-PE, CD57-FITC, HLA-DR-ECD, CD45RA-ECD, CD27-PC5, and CD38-PE (Beckman Coulter, Hialeah, FL), CD45RA-FITC, and CD45RO-PC7 (BD Biosciences, CA) and analyzed by 5-color flow cytometry performed with a Beckman Coulter Cytomics FC500 MPL flow cytometer. T-cell subsets were defined as follows: naive T cells 
CD28
Ϫ . Statistical analyses. Continuous variables are expressed as medians with the interquartile ranges (IQR), and categorical variables are expressed as numbers and percentages. Differences between the groups were analyzed using a chi-square test to compare categorical variables, while the Mann-Whitney U test (nonpaired variables) and Wilcoxon test (paired variables) were used for continuous variables. All P values of Ͻ0.05 were considered significant. Statistical analyses were performed using the Statistical Package for the Social Sciences software (SPSS 17.0; Chicago, IL), and the graphics were generated with Prism, version 5.0 (GraphPad Software, Inc.).
RESULTS

Baseline characteristics of the patients.
The baseline characteristics of the 70 patients included in this study are shown in Table 1 . Compared with the control group, MCT ϩ patients exhibited higher CD4
ϩ T-cell counts, a lower HIV load, older age, a greater length of time since HIV diagnosis, and a higher frequency of HCV coinfection. Moreover, MCT Ϫ patients had the lowest nadir and CD4
ϩ T-cell counts, as previously described (22) , and a higher proportion of these patients were in CDC stage C.
MVC-specific effects after 8-day therapy. The HIV viral load and T-cell levels were not modified in the MCT Ϫ group. The HIV viral load decreased significantly (P Ͻ 0.001), and the median T-cell levels increased significantly in the MCT ϩ group and the control group, as we previously reported (20) ( Table 2 ). T-cell increases were similar between the MCT ϩ group and the control group (P value of 0.284 for CD4 ϩ and P value of 0.251 for CD8 ϩ T cells).
No differences in any of the studied biomarkers were observed in the MCT Ϫ group ( Fig. 2A to E) . CD8 ϩ T-cell activation and senescence levels increased in the MCT ϩ group, while these levels remained unchanged in the control group. No changes in CD4 ϩ T-cell activation or senescence levels were observed in either group ( Fig. 2A to D) . Regarding these biomarkers in the T-cell subsets, only TemRA CD4 ϩ T-cell senescence levels decreased in the MCT ϩ group (P ϭ 0.044) (Fig. 3A) . Regarding inflammatory markers, sCD14 levels significantly increased in the control group while they remained stable in the MCT ϩ group ( Fig. 2E ; see also MCT. Afterward (8 days), the patients were divided into two groups, MCT Ϫ and MCT ϩ , according to the virological response experienced after the MCT. According to this response, the patients were followed for 12 weeks on MVCcontaining (MCT ϩ patients) or MVC-sparing (MCT Ϫ patients) cART. The same study variables were analyzed at day 8 and week 12 in a control group of patients on MVC-sparing cART.
MCT
ϩ patients (80.0%), and 13 patients from the control group were included in the follow-up studies (52.0%). The baseline characteristics of these subgroups were similar to those from the whole study population (see Table S1 in the supplemental material). Background antiretroviral treatments of the different groups are shown in Table S2 in the supplemental material.
All the groups demonstrated significantly decreased HIV viral load levels (Table 2) . CD4
ϩ T-cell counts significantly increased in all groups. CD8 ϩ T-cell counts increased in the MCT ϩ and MCT Ϫ groups, while in the control group, these levels remained unchanged ( Table 2 ). The median CD4 ϩ T-cell increases (ranges) were similar between the MCT ϩ group and the control group (92 [34 to 162] and 173 [68 to 210], respectively; P ϭ 0.139).
CD4 ϩ T-cell activation levels tended to increase, and CD4 ϩ T-cell senescence levels significantly increased only in the groups on MVC-sparing cART ( Fig. 4A and B) . Moreover, only senescent TemRA CD4 ϩ T-cell levels showed a decreasing trend in the MCT ϩ group, similar to the results of the 8-day treatment (P ϭ 0.061) (Fig. 3B) . CD8 ϩ T-cell activation levels tended to decrease in the MCT ϩ group and significantly decreased in the control group (Fig. 4C) . When we considered the activation phenotype to be CD38 ϩ HLA-DR ϩ , we found similar results with even more significant decreases (P value of 0.008 for MCT ϩ patients and P value of 0.048 for control group patients). Additionally, increased CD8 ϩ T-cell senescence levels were found only in the control group, and these differences remained significant when the outlier value at week 12 was eliminated from the control group (Fig. 4D) . Interestingly, sCD14 levels decreased in the MCT ϩ patients, and there was a decreasing trend in the MCT Ϫ group. However, there were no changes in the control group ( 
DISCUSSION
Eight days of MVC monotherapy allowed us to determine the specific effects of blocking R5 on several HIV disease progressionrelated biomarkers. First, MVC did not modify any biomarkers in MCT Ϫ patients. In contrast, an increase in both CD8 ϩ T-cell activation and senescence levels and a favorable profile of D dimer and sCD14 levels were observed in MCT ϩ patients. In addition, 12 weeks of MVC-containing cART significantly increased the absolute CD8 ϩ T-cell counts and maintained lower CD4 ϩ T-cell senescence levels compared with the values for the cART group. Similarly, MVC-containing cART decreased sCD14 levels compared with those of an MVC-sparing cART.
We have previously shown that MVC-specific effects on T-cell changes are dependent on the drug's antiretroviral activity (20) . We analyzed this issue in depth with respect to HIV disease progression biomarkers. In accordance with our previous results, the first important finding of this study is that MVC had no effect on any of the measured parameters in the patients who had no virological response. This finding supports the fact that an antiretroviral effect is necessary to observe the specific immune effects of MVC in relation to these markers. Thus, MVC will not have any immunomodulatory effect on patients who are insensitive to the drug, at least on the parameters studied herein, a finding which is in contrast to what has been previously suggested (23) . Surprisingly, the MVC-specific effect after 8 days was an increase in CD8 ϩ T-cell activation and senescence levels. The fact that these effects ceased at the onset of the cART after the MCT, even with MVC-containing cART, may suggest that blocking CCR5 causes early lymphocyte redistribution from the lymph nodes to blood (5, 21) rather than a proactivation effect of MVC. In fact, T-cell redistribution from lymph to blood has been shown to occur early after HAART, although this effect has not been studied at such a short term as in this study (5) . In addition, MVC showed a favorable specific effect on soluble markers associated with HIV disease progression, demonstrated by significant decreases in D dimer together with sCD14 stabilization and a trend toward decreasing hsCRP levels compared with the control group, although levels at day 8 were similar for the two therapies. The results presented here shed light on the potential clinical beneficial effects of MVC-containing cART. In fact, when we analyzed the short-term cART effect, we observed how MVC differentially diminished sCD14 levels. This decrease in a marker of innate immune activation may have important clinical implications because high sCD14 levels have been independently associated with mortality in HIV-infected patients (24) . The decrease of D dimer levels which have been associated with lower cardiovascular risk in HIV-infected patients (4) could also be clinically relevant. However, these results contradict the increase in sCD14 levels observed after MVC intensification in a recent study (14) . In fact, the higher levels found in that study were statistically significant after 24 to 48 weeks, but not at 12 weeks, on cART, and the previous study included a very different set of patients (under an MVC intensification strategy, on suppressive cART, and with much higher CD4 ϩ T-cell levels than patients in the present work). Better profiles of MVC were also found in cellular markers in that study, in which MVC was associated with stability in CD4 ϩ T-cell activation and T-cell senescence markers. In contrast to conventional cART, we found that MVC-containing cART did not change the absolute T-cell numbers with the absence of CD28 expression in CD4 ϩ T cells. CD28 is a costimulatory T-cell molecule whose absence on the T-cell surface has been linked to replicative senescence and HIV-1 progression (6). These differences may be due to the backbone therapy accompanying MVC in the new cART compared with the control group. However, when patient treatment variables were adjusted, the same effects on T-cell senescence were observed (data not shown). The trend observed in CD4
ϩ T-cell activation levels is in agreement with the previous data of the MERIT substudy (10) , in which cART with MVC versus the same therapy including efavirenz showed a trend toward higher deactivation of CD4 ϩ T-cell levels after 24 weeks. However, we did not observe changes in activated CD4
ϩ T-cell levels in the MCT ϩ group, a result which is contrary to the surprising trend toward increasing CD4 ϩ T-cell activation in the conventional cART group. In cART, decreases in CD4 ϩ T-cell activation levels have been observed at a longer follow-up time (2, 9, 13) and may be the reason for such discrepancies. In contrast, MVC was associated with a decrease in the senescence levels of TemRA CD4 ϩ , terminally differentiated CD4 ϩ T cells, which are mostly replicatively senescent. The long-term causes and effects of this decrease are unknown at present.
This work has some limitations, including the fact that groups that underwent MCT were pretreated and were older, had a greater length of time since HIV diagnosis, and had a higher proportion of HCV coinfection than the control group, which was composed of naive patients. This different composition of the groups was mandatory when this study was designed and performed because MVC prescription in Europe was indicated only in pretreated patients at that time. These differences may negatively impact the parameters measured in the MCT ϩ group. However, we observed similar CD4 ϩ T-cell changes after therapy and, in general, a more favorable immunological profile in these patients than in the control group. Therefore, we would expect even greater differences favoring the MCT ϩ group if the variables mentioned above were controlled for among the patients. We do not know if a longer time on MVC monotherapy would have favored additional MVC-specific effects. This final limitation may also be considered a strength of the study, reflecting the unique design of the MCT, which led us to analyze the MVC-specific effect. In conclusion, MVC-specific effects induced a favorable profile in D dimer and sCD14 levels, a result which is opposite of the effects observed in T-cell activation. The reversible nature of the latter effect after cART suggests that this phenomenon is compatible with a redistribution of T cells from the lymph nodes in the short term. MVC-containing cART seems to induce a more favorable profile in HIV disease progression-related markers, such as sCD14, CD4
ϩ T-cell activation, and T-cell senescence. These ob- servations are particularly important in the current cART era, in which new immunotherapeutic approaches to decrease HIV disease progression markers, beyond the antiretroviral effect, are needed.
